| US 7,351,842 B2 | ||
| Compounds for treatment of cardiac arrhythmia and methods of use | ||
| Pascal Druzgala, Santa Rosa, Calif. (US) | ||
| Assigned to ARYx Therapeutics, Inc., Fremont, Calif. (US) | ||
| Filed on Jun. 12, 2006, as Appl. No. 11/423,559. | ||
| Application 11/423559 is a continuation of application No. 11/101995, filed on Apr. 08, 2005, granted, now 7,105,568. | ||
| Claims priority of provisional application 60/560917, filed on Apr. 09, 2004. | ||
| Prior Publication US 2006/0276535 A1, Dec. 07, 2006 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C07D 307/02 (2006.01); A61K 31/34 (2006.01) | ||
| U.S. Cl. 549—467 [549/468; 514/469] | 42 Claims |
1. A pharmaceutically acceptable salt of a compound of structural Formula II:
 R1 is H or C1-C10 alkyl;
R2 is H or optionally substituted C1-C10 alkyl, heteroalkyl, cycloalkyl or heterocycloalkyl;
n=0 to 4;
p=0 or 1;
R3 and R4 are, independently, H or C1-C4 alkyl, and wherein the salt is selected from hydrochloride, hydrobromide, p-toluenesulfonate, phosphate, sulfate, perchlorate,
acetate, trifluororacetate, propionate, citrate, malonate, succinate, lactate, oxalate, (L)-tartrate, (D)-tartrate, meso-tartrate,
benzoate, alkali metal, morpholine, piperidine, dimethylamine, and diethylamine salts.
|